Updated clinical and laboratory diagnostic criteria of JMML
I. Clinical and hematologic features (all 4 features mandatory) |
• Peripheral blood monocyte count >1 × 109/L |
• Blast percentage in peripheral blood and bone marrow <20% |
• Splenomegaly |
• Absence of Philadelphia chromosome (BCR/ABL rearrangement) |
II. Oncogenetic studies (1 finding is sufficient) |
• Somatic mutation in PTPN11* or K-RAS* or N-RAS*† |
• Clinical diagnosis of NF-1 or germline NF1 mutation |
• Germline CBL mutation and loss of heterozygosity of CBL‡ |
III. Only for those patients (10% of the whole number) without any oncogenetic parameter, besides the clinical and hematologic features listed under I, at least 2 of the following criteria have to be fulfilled: |
• Monosomy 7 or any other chromosomal abnormality |
• HbF increased for age |
• Myeloid precursors on peripheral blood smear |
• Spontaneous growth or GM-CSF hypersensitivity in colony assay |
• Hyperphosphorylation of STAT5 |
I. Clinical and hematologic features (all 4 features mandatory) |
• Peripheral blood monocyte count >1 × 109/L |
• Blast percentage in peripheral blood and bone marrow <20% |
• Splenomegaly |
• Absence of Philadelphia chromosome (BCR/ABL rearrangement) |
II. Oncogenetic studies (1 finding is sufficient) |
• Somatic mutation in PTPN11* or K-RAS* or N-RAS*† |
• Clinical diagnosis of NF-1 or germline NF1 mutation |
• Germline CBL mutation and loss of heterozygosity of CBL‡ |
III. Only for those patients (10% of the whole number) without any oncogenetic parameter, besides the clinical and hematologic features listed under I, at least 2 of the following criteria have to be fulfilled: |
• Monosomy 7 or any other chromosomal abnormality |
• HbF increased for age |
• Myeloid precursors on peripheral blood smear |
• Spontaneous growth or GM-CSF hypersensitivity in colony assay |
• Hyperphosphorylation of STAT5 |